REMEDi4ALL - Standard Operating Procedure - Two drug combination test: detection of synergetic anti-proliferative effect in cancer cell lines

This SOP describes the application of the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) for detection of the synergetic anti-proliferative effect in pancreatic cancer cell lines based on small molecule treatment. It describes the procedure of compound- and cell-preparation to detect and analyse the anti-proliferative synergetic effect of compounds. IMPORTANT: for each new cell line and each new tested compound pair the cell number/well and the specific CC50s of tested compounds should be evaluated before the application of this SOP. See also Standard Operating Procedure SOP-R4A-1.1 “Drugs combination screening”

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-10-08
DOI
https://doi.org/10.5281/zenodo.17293604
Primary Topic
bioluminescence and chemiluminescence research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

REMEDi4ALL - Standard Operating Procedure - Two drug combination test: detection of synergetic anti-proliferative effect in cancer cell lines

Zenodo (CERN European Organization for Nuclear Research)
bioluminescence and chemiluminescence research
article

REMEDi4ALL - Standard Operating Procedure - Two drug combination test: detection of synergetic anti-proliferative effect in cancer cell lines

article en

Abstract

This SOP describes the application of the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) for detection of the synergetic anti-proliferative effect in pancreatic cancer cell lines based on small molecule treatment. It describes the procedure of compound- and cell-preparation to detect and analyse the anti-proliferative synergetic effect of compounds. IMPORTANT: for each new cell line and each new tested compound pair the cell number/well and the specific CC50s of tested compounds should be evaluated before the application of this SOP. See also Standard Operating Procedure SOP-R4A-1.1 “Drugs combination screening”

Zenodo (CERN European Organization for Nuclear Research)
Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
Good health and well-being
Openalex Percentile: Top 46%
bioluminescence and chemiluminescence research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.